A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation

American Journal of Transplantation

Volumn 16, Issue 7, 2016, Pages 2085-2096

  Shuker, N ^a   Bouamar, R ^a   van Schaik, R H N ^a   Clahsen van Groningen, M C ^a   Damman, J ^b   Baan, C C ^a   van de Wetering, J ^a   Rowshani, A T ^a   Weimar, W ^a   van Gelder, T ^a   Hesselink, D A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

calcineurin inhibitor: tacrolimus; clinical research practice; genetics; immunosuppressant; immunosuppression immune modulation; kidney transplantation nephrology; pharmacokinetics pharmacodynamics

Indexed keywords

TACROLIMUS;

ACUTE CORONARY SYNDROME; ACUTE GRAFT REJECTION; ACUTE KIDNEY TUBULE NECROSIS; ADULT; AGED; ANEMIA; ARTICLE; BASAL CELL CARCINOMA; BK VIRUS INFECTION; BLEEDING; BLOOD TOXICITY; BODY WEIGHT; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CYTOCHROME P450 3A5 GENE; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; EPSTEIN BARR VIRUS INFECTION; FEMALE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; GENE; GENOTYPE; GRAFT RECIPIENT; HEADACHE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE OVERLOAD; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYDRONEPHROSIS; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY INFARCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER DYSFUNCTION; LIVING DONOR; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; NUTRITIONAL DISORDER; OPPORTUNISTIC INFECTION; PHARMACOGENETICS; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREMOR; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE INCONTINENCE; WOUND INFECTION;

EID: 84976488593     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13691     Document Type: Article

References (35)

1. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2011 annual data report: Kidney. Am J Transplant 2013; 13: 11–46.
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623–653.
3. Kamdem LK, Streit F, Zanger UM, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51: 1374–1381.
4. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315–1324.
5. Hesselink DA, Bouamar R, Elens L, van Schaik RHN, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet 2014; 53: 123–139.
6. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–391.
7. Pallet N, Jannot AS, El Bahri M, et al. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. Am J Transplant 2015; 15: 800–805.
8. van Gelder T, van Schaik RH, Hesselink DA. Practicability of pharmacogenetics in transplantation medicine. Clin Pharmacol Ther 2014; 95: 262–264.
9. Hesselink DA, van Schaik RHN, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245–254.
10. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA. The effect of CYP3A5 6986A > G and ABCB1 3435C > T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: A systematic review and meta-analysis. Pharmacogenet Genomics 2012; 22: 642–645.
11. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3): S1–S157.
12. MacPhee IAM, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914–919.
13. van Gelder T, Hesselink DA. Dosing tacrolimus based on CYP3A5 genotype: Will it improve clinical outcome? Clin Pharmacol Ther 2010; 87: 640–641.
14. ® tacrolimus capsules, tacrolimus injection (for intravenous infusion only). 2009.
15. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272–283.
16. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247–254.
17. Van Schaik RHN, Van Der Heiden IP, Van Den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48: 1668–1671.
18. Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87 : 721–726.
19. Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18: 2409–2414.
20. Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol 2003; 56: 327–330.
21. Birdwell KA, Grady B, Choi L, et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet Genomics 2012; 22: 32–42.
22. Jacobson PA, Oetting WS, Brearley AM, et al. Novel polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortium. Transplantation 2011; 91: 300–308.
23. de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DRJ. The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 2011; 12: 1281–1291.
24. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57: 1574–1583.
25. Werk AN, Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther 2014; 96: 340–348.
26. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 2011; 72: 948–957.
27. Boughton O, Borgulya G, Cecconi M, Fredericks S, Moreton-Clack M, MacPhee IAM. A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. Br J Clin Pharmacol 2013; 76: 425–431.
28. Vadivel N, Garg A, Holt DW, Chang RWS, MacPhee IAM. Tacrolimus dose in black renal transplant recipients. Transplantation 2007; 83: 997–999.
29. MacPhee IA, Holt DW. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. Transplantation 2008; 85: 163–165.
30. Hesselink DA, van Schaik RHN, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18: 339–348.
31. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: From bench to byte—an update of guidelines. Clin Pharmacol Ther 2011; 89: 662–673.
32. Bridwell KA, Decker B, Barbarino JM, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for cyp3a5 genotype and tacrolimus dosing. Clin Pharmacol Ther 2015; 98: 19–24.
33. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562–2575.
34. Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H, Daloze P. The challenge of achieving target drug concentrations in clinical trials: Experience from the symphony study. Transplantation 2009; 87: 1360–1366.
35. Bouamar R, Shuker N, Hesselink DA, et al. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: A pooled analysis from three randomized-controlled clinical trials. Am J Transplant 2013; 13: 1253–1261.